Investment Commentary
Source - The Motley Fool
A collaboration between Janssen and Idenix is the highlight of this video. The collaboration will evaluate combinations using the following investigational HCV drugs; simeprevir formerly referred to as TMC435 a protease inhibitor developed by Janssen R&D Ireland and Medivir, TMC647055 a polymerase inhibitor by Janssen and Idenix's IDX719 a NS5A inhibitor. The clinical hold on IDX184 in relation to the outcome of Bristol-Myers tragic trial with drug BMS-986094 is also included in the video.
Related-
New Interferon-free Development Program
Alan Franciscus
Editor-in-Chief, HCV Advocate
January 28 2013 - Medivir announced a collaboration between Medivir/Janssen and Idenix for the clinical development of multiple HCV inhibitors with and without ribavirin—all the studies will be interferon-free.
Continue reading....
Press Release
Medivir: Phase II all-oral combination studies of Simeprevir, TMC647055 and IDX719 for the treatment of Hepatitis C to be initiated shortly
No comments:
Post a Comment